Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is a leading provider of integrated, temperature-controlled supply chain solutions for the life sciences industry. The company has a strong focus on supporting the cell and gene therapy market, which is a fast-growing and highly promising segment. With its comprehensive portfolio of services and products, strong revenue visibility, and growing customer base, CryoPort is well-positioned to capitalize on the growth opportunities in the cell and gene therapy market. Moreover, the company's strong financial performance and margin expansion potential are promising signs for future profitability.

Bears say

CryoPort is expected to have strong commercial revenues, but their guidance is based strictly on therapies currently approved, leaving room for potential revenue declines. Additionally, there are risks associated with clinical trial progression, competition in the market, and macro pressures on their MVE business. There is potential for upside if there are more approvals for cell and gene therapies distributed through CryoPort's logistics platform, but there is also a risk of slower approvals and increased competition in the cold-chain logistics market.

CryoPort (CYRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.